FibroBiologics will present on fibroblast-based therapies for chronic diseases at a conference in Freiburg, Germany, on March 27, 2025. FibroBiologics, Inc., a biotechnology company focused on ...
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
Hypertrophic scarring affects a large proportion of patients following burns, trauma, or surgery and arises from prolonged fibroblast hyperactivity and excessive extracellular matrix accumulation.
Jen Davis (left) and Bella Reichardt (right) conducting research in a lab for genetic engineering of heart fibroblasts.at the UW Medicine Institute for Stem Cell and Regeneration Medicine. Fibroblasts ...
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results